288 related articles for article (PubMed ID: 16707367)
1. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma.
Mhawech P; Uchida T; Pelte MF
Hum Pathol; 2002 Nov; 33(11):1136-40. PubMed ID: 12454820
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
5. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
6. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
8. Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases.
Ormsby AH; Haskell R; Jones D; Goldblum JR
Mod Pathol; 2000 Jan; 13(1):46-51. PubMed ID: 10658909
[TBL] [Abstract][Full Text] [Related]
9. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical study of urine cytological preparations from secondary prostatic adenocarcinoma involving the urinary bladder.
Mai KT; Ahmed I; Robertson SJ; Belanger EC; Veinot JP; Islam S
Diagn Cytopathol; 2008 Oct; 36(10):715-20. PubMed ID: 18773445
[TBL] [Abstract][Full Text] [Related]
11. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
12. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
13. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
Martínez-Rodríguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
[TBL] [Abstract][Full Text] [Related]
16. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?
Alshenawy HA; Saied E
APMIS; 2015 Sep; 123(9):772-8. PubMed ID: 26200506
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.
Shah RB; Kunju LP; Shen R; LeBlanc M; Zhou M; Rubin MA
Am J Clin Pathol; 2004 Oct; 122(4):517-23. PubMed ID: 15487448
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
Varma M; Jasani B
Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
[TBL] [Abstract][Full Text] [Related]
20. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]